Drug Profile
NAL 3216
Alternative Names: NAL3216Latest Information Update: 09 Sep 2016
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Anti-infectives; Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Onychomycosis
Most Recent Events
- 09 Sep 2016 Discontinued - Clinical-Phase-Unknown for Onychomycosis (Topical)
- 17 Aug 2016 NAL 3216 is available for licensing as of 17 Aug 2016. http://www.nalpharma.com/licensing.php?id=10&lang=en
- 17 Aug 2016 Clinical trials in Onychomycosis (Topical)